Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00451763

Enrollment

Registered

2007-03-23

Start date

2006-01-31

Completion date

2007-12-31

Last updated

2008-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retina, Telangiectasis

Keywords

Fovea centralis/pathology, Fundus oculi, Retinal neovascularization, Telangiectasis/diagnosis, Tomography, optical coherence, Vitreous Body/drug effects

Brief summary

Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia. In Idiopathic Macular Telangiectasia, proliferative changes occur in the deep retinal capillary network, leading to intraretinal neovascularization that, unlike in age-related macular degeneration, seems to be retinal rather than choroidal in origin. Before the hemorrhagic and fibrotic state, these vessels may lead to exudation and decrease in the visual acuity. Long-term visual prognosis in patients with this complication may be poor and treatment with laser photocoagulation is unproven. Although newly reported treatment, by photodynamic therapy for neovascular membrane associated with Idiopathic Macular Telangiectasia, may show vision and angiographic stability in a few cases, the improvement may be transient. VEGF has been implicated as the major angiogenic stimulus responsible for neovascularization in AMD, ensuing specific anti-VEGF treatment in these cases. The purpose of the study is to evaluate intravitreal injection of bevacizumab (1.25mg/0.05ml) in the treatment of Idiopathic Macular Telangiectasia.

Interventions

DRUGIntravitreal Injection of Bevacizumab (1.25 mg/0.05ml)

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with idiopathic macular telangiectasia * patient consent

Exclusion criteria

* heart attack or cerebrovascular attack * previous treatment for others retinopathy * media opacities that preclude visualization of the fundus * inability to understands the implications of the protocol

Design outcomes

Primary

Measure	Time frame
Optical coherence tomography	—
Fluorescein angiography	—
Visual acuity	—

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026